Optimize your pharmaceutical portfolio strategy

In Vivo

Regular Acceptance Of Simulation Studies More Likely In 2020s

By William Masters 17 Feb 2020

Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

In Vivo

A Tale Of Two Pipelines

By Dennis Chang; Keith Flaherty; Uciane Scarlett 29 Jan 2020

Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

In Vivo

ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

By William Looney 29 Jan 2020

The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

29 Jan 2020

Datamonitor Healthcare

Cardiovascular Disease Epidemiology Overview

By Niharika Dandamudi 28 Jan 2020

Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.

Biomedtracker, Datamonitor Healthcare

2019 Post-ASH Conference Report Extract

28 Jan 2020

Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.

In Vivo

Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

By William Looney 27 Jan 2020

Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

In Vivo

Outlook 2020 Report

18 Dec 2019

Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

In Vivo

Medtechs Enter The Decade of Digital, Consumers and Wellness

By Ashley Yeo 11 Dec 2019

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

In Vivo

Critical Insights into Market Access

10 Dec 2019

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

In Vivo

Brexit To And Fro Continues Into Fresh Decade

By Ian Schofield 06 Dec 2019

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 28 Nov 2019

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

In Vivo

MHealth And Research In Oncology

By Niharika Dandamudi 20 Nov 2019

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”

In Vivo

How Proximity Creates Partnerships

By William Looney 08 Nov 2019

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.